Quick Answer
Aldeyra Therapeutics, Inc. reported Long Term Debt of $0.00 for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -100.0% in Long Term Debt from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2013 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $972.4 thousand | Q2 2014: $815.8 thousand | Q3 2014: $1.24 million | Q1 2015: $1.07 million | Q2 2015: $961.5 thousand | Q3 2015: $1.28 million | Q1 2016: $1.10 million | Q2 2016: $992.6 thousand | Q3 2016: $883.3 thousand | Q1 2017: $1.13 million | Q2 2017: $1.02 million | Q3 2017: $905.3 thousand | Q1 2018: $1.11 million | Q2 2018: $995.3 thousand | Q3 2018: $882.8 thousand | Q3 2019: $14.39 million | Q1 2020: $14.67 million | Q2 2020: $13.92 million | Q3 2020: $12.69 million | Q1 2021: $10.14 million | Q2 2021: $15.34 million | Q3 2021: $15.42 million | Q1 2022: $15.59 million | Q2 2022: $10.74 million | Q3 2022: $3.30 million | Q1 2023: $14.97 million | Q2 2023: $10.13 million | Q3 2023: $2.66 million | Q1 2024: $0.00 | Q3 2024: $15.00 million | Q1 2025: $15.10 million | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 12 years of available data (2013 to 2025), Aldeyra Therapeutics, Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $15.00 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $14.92 million | Fiscal year 2021: $15.50 million | Fiscal year 2020: $11.43 million | Fiscal year 2019: $14.53 million | Fiscal year 2017: $1.22 million | Fiscal year 2016: $1.24 million | Fiscal year 2015: $1.21 million | Fiscal year 2014: $1.18 million | Fiscal year 2013: $1.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: